Mantle Cell Lymphoma | Specialty

Dr. Leslie Discusses CAR T-Cell Therapy in MCL

April 3rd 2018

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the developing role of chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

Dr. Goy Discusses Ibrutinib With Venetoclax in MCL

March 26th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in the treatment of patients with mantle cell lymphoma (MCL).

Dr. Hill Discusses Biomarker Research in MCL

March 22nd 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses biomarker research in mantle cell lymphoma (MCL).

Goy Lends Insight on Acalabrutinib and Ibrutinib in MCL

March 22nd 2018

Andre Goy, MD, discusses the excitement surrounding acalabrutinib, as well as emerging ibrutinib combination strategies for the treatment of patients with mantle cell lymphoma.

Dr. Ruan Discusses Biomarkers in MCL

March 19th 2018

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses biomarkers in mantle cell lymphoma.

Dr. Goy Discusses BTK Inhibitors in MCL

March 13th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the role of Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of patients with mantle cell lymphoma (MCL).

Dr. Schuster on Long-Term Outcomes of Lenalidomide and Rituximab in MCL

March 8th 2018

Stephen J. Schuster, MD, professor of hematology/oncology at the University of Pennsylvania Abramson Cancer Center, discusses long-term outcomes of lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).

Flinn Sheds Light on Advances in MCL and Other Lymphomas

March 6th 2018

Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.

Dr. Hill Discusses Combinations in MCL

February 26th 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses combinations for the treatment of patients with mantle cell lymphoma.

Ibrutinib Continues to Demonstrate Effectiveness in MCL

February 23rd 2018

Brad S. Kahl, MD, discusses the latest data for ibrutinib and highlights emerging treatments in mantle cell lymphoma.

Dr. Ruan Discusses BTK Inhibitors in MCL

February 22nd 2018

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses BTK inhibitors for the treatment of patients with mantle cell lymphoma (MCL).

Dr. Goy on Acalabrutinib Versus Ibrutinib in MCL

February 20th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses acalabrutinib (Calquence) versus ibrutinib (Imbruvica) in the treatment of patients with mantle cell lymphoma.

Combinations Explored in MCL After Second BTK Inhibitor Approval

February 19th 2018

Brian T. Hill, MD, PhD, discusses acalabrutinib and ibrutinib’s efficacy in patients with mantle cell lymphoma and highlights emerging novel strategies in the treatment landscape.

MCL Expert Highlights Recent Advancements in Field

February 16th 2018

Peter Martin, MD, reflects on the MCL data presented at the 2017 ASH Annual Meeting, and shares his insight on the future of clinical trials in the disease.

Dr. Hill Discusses BTK Inhibitors in Mantle Cell Lymphoma

February 14th 2018

Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses BTK inhibitors in mantle cell lymphoma (MCL).

Dr. Ruan on Long-Term Findings With Lenalidomide Plus Rituximab in MCL

February 14th 2018

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses long-term findings with lenalidomide (Revlimid) plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

Dr. Kaplan Discusses Combinations With Rituximab for MCL

February 7th 2018

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, division of Hematology-Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses combinations with rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).

Dr. Goy Discusses Combinations in Mantle Cell Lymphoma

January 27th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses combinations in mantle cell lymphoma.

Advances and Research Needs in Lymphoma

January 26th 2018

Investigating CAR T-Cell Therapy in Lymphoma

January 26th 2018